Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Practical Measures of Ruxolitinib’s Clinical Benefit

Clin Lymphoma Myeloma Leuk; ePub 2017 May 12; Miller, et al

Ruxolitinib’s benefit in patients with myelofibrosis can be assessed using a number of methods that are easily accessed in the community setting, according to a post hoc analysis of data from COMFORT-I trial involving 150 individuals.

Investigators evaluated changes over 12 weeks in spleen size, patient-reported outcomes, body weight, and serum albumin levels in 5 ruxolitinib-treated subgroups divided based on spleen length. Among the results:

  • Ruxolitinib was linked with improved spleen volume in all subgroups, including those with worsening spleen length.
  • Body weight and serum albumin levels also improved.
  • Greater reductions in spleen length were linked with prolonged overall survival.

Citation:

Miller C, Komrokji R, Mesa R, Sun W, Montgomery M, Verstovsek S. Practical measures of clinical benefit with ruxolitinib therapy: An exploratory analysis of COMFORT-I. [Published online ahead of print May 12, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.05.015.